COMMUNIQUÉS West-GlobeNewswire

XOMA Royalty Announces Closing of Its Acquisition by Ligand
14/07/2026
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. [...]
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
14/07/2026
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering IRVINE, Calif., July 14, 2026 ( [...]
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
14/07/2026
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term [...]
Cannara Announces a Long-Term International Cannabis Supply Agreement with Curaleaf International Limited
14/07/2026
MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Captain James A. Lovell Federal Health Care Center to Treat Post-Traumatic Stress With Virtual Reality Donated by Nonprofit SoldierStrong
14/07/2026
STAMFORD, Conn., July 14, 2026 (GLOBE NEWSWIRE) -- The Captain James A. Lovell Health Care Center in North Chicago, Illinois, is the country’s latest Department of Veterans Affairs facility to partner with national [...]
Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
14/07/2026
SAN FRANCISCO and YAVNE, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for [...]
Lanier Recovery Center earns BBB accreditation and A rating
14/07/2026
New Suwanee rehab builds a credentials-first program, earning BBB accreditation less than a year after opening Suwanee, GA, July 14, 2026 (GLOBE NEWSWIRE) -- Lanier Recovery Center has earned accreditation from the [...]
PetMeds and Rural King Expand Access to Pet Healthcare Through New Online Pharmacy Platform
14/07/2026
Rural King customers can now shop medications, prescription food and other pet health products through a co-branded digital experience DELRAY BEACH, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing [...]
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. [...]
FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer
14/07/2026
Phase 1/2 trial of SOT109 in patients with advanced unresectable or metastatic colorectal cancer expected to commence in Q3 2026 PRAGUE and BASEL, Switzerland and BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- SOTIO Biotech [...]
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026
14/07/2026
EMJX Shifted from “Stress” to “Mixed” for Bitcoin Company Files Updated Investor Presentation Outlining Performance and Strategy Management to Host Fireside Chat Today at 10:30am ET NORTH PALM BEACH, Fla., July 14, 2026 [...]
Cannara annonce la conclusion d’une entente internationale à long terme d’approvisionnement en cannabis avec Curaleaf International Limited
14/07/2026
MONTRÉAL, 14 juill. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous ») ( TSX: LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de qualité [...]
Applied Biologics Announces Successful Manufacture of First Research Construct for Disease-Modifying Osteoarthritis Gene Therapy Program
14/07/2026
SCOTTSDALE, Ariz., July 14, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
14/07/2026
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase 2b [...]
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
14/07/2026
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 Preclinical data for sutacimig in Factor VII deficiency (FVIID) [...]
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
14/07/2026
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to [...]
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
14/07/2026
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support darlifarnib’s potential [...]
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
14/07/2026
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No [...]
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
14/07/2026
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is [...]

Pages